Expanesthetics is the global leader in the search for new, improved inhalation general anesthetics. We are utilizing our licensed screening technology to identify molecules that may contain benefits over existing anesthetics with fewer unwanted effects.
Anesthesia providers continue to affirm the need for improvements in current anesthetic agents as demonstrated by our market research. In addition, market conditions such as changes in patient demographics, increased focus on improved surgical outcomes, and "pay-for-performance" have created ideal conditions for the development of new anesthetic agents with improved properties and a reduced side effect profile.
The global anesthetic drug market is generally estimated to be valued in the billions of dollars. To our knowledge, no other company is making investments in R&D to develop the next generation of inhalation anesthetic agents.
Because the molecular mechanism of the inhalation anesthetics has been unknown, an efficient screening process for identifying new candidates has not been possible. With desflurane first appearing in the United States in 1992 and sevoflurane first appearing in the United States in 1995, there have been no new molecular entities for inhalation anesthesia in the United States in over 20 years. Expanesthetics is built on a major discovery regarding the molecular mechanism of the inhalation anesthetics that has given us a roadmap and an efficient screening process for identifying new inhalation anesthetic candidates.